Skip to main content
Journal cover image

Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.

Publication ,  Journal Article
Upadhya, B; Kitzman, DW
Published in: Am J Cardiovasc Drugs
August 2017

Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common form of HF in patients older than 65 years. Among elderly women living in the community, HFpEF comprises nearly 90% of incident HF cases. The health and economic impact of HFpEF is at least as great as that of HF with reduced ejection fraction (HFrEF), with similar severity of acute hospitalization rates and substantial mortality. Despite the importance of HFpEF, our understanding of its pathophysiology is incomplete, and optimal treatment remains largely undefined. Unlike the management of HFrEF, there is a paucity of large evidence-based trials demonstrating morbidity and mortality benefit for the treatment of HFpEF. The agents tested in trials to date, which were based upon an incomplete understanding of the pathophysiology of HFpEF, have not been positive. There is an urgent need to understand HFpEF pathophysiology and to focus on developing novel therapeutic targets.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiovasc Drugs

DOI

EISSN

1179-187X

Publication Date

August 2017

Volume

17

Issue

4

Start / End Page

283 / 298

Location

New Zealand

Related Subject Headings

  • Stroke Volume
  • Humans
  • Heart Failure
  • Healthy Lifestyle
  • Forecasting
  • Disease Management
  • Cardiovascular System & Hematology
  • Cardiotonic Agents
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Upadhya, B., & Kitzman, D. W. (2017). Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. Am J Cardiovasc Drugs, 17(4), 283–298. https://doi.org/10.1007/s40256-017-0219-2
Upadhya, Bharathi, and Dalane W. Kitzman. “Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Am J Cardiovasc Drugs 17, no. 4 (August 2017): 283–98. https://doi.org/10.1007/s40256-017-0219-2.
Upadhya B, Kitzman DW. Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. Am J Cardiovasc Drugs. 2017 Aug;17(4):283–98.
Upadhya, Bharathi, and Dalane W. Kitzman. “Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.Am J Cardiovasc Drugs, vol. 17, no. 4, Aug. 2017, pp. 283–98. Pubmed, doi:10.1007/s40256-017-0219-2.
Upadhya B, Kitzman DW. Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. Am J Cardiovasc Drugs. 2017 Aug;17(4):283–298.
Journal cover image

Published In

Am J Cardiovasc Drugs

DOI

EISSN

1179-187X

Publication Date

August 2017

Volume

17

Issue

4

Start / End Page

283 / 298

Location

New Zealand

Related Subject Headings

  • Stroke Volume
  • Humans
  • Heart Failure
  • Healthy Lifestyle
  • Forecasting
  • Disease Management
  • Cardiovascular System & Hematology
  • Cardiotonic Agents
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology